NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells $49,545,943.00 in Stock

NeuroPace, Inc. (NASDAQ:NPCE) major shareholder Ltd. Kck sold 5,270,845 shares of the company’s stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $9.40, for a total value of $49,545,943.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

NeuroPace Price Performance

NPCE opened at $14.23 on Friday. The company has a debt-to-equity ratio of 6.03, a current ratio of 5.59 and a quick ratio of 4.77. NeuroPace, Inc. has a 12 month low of $5.45 and a 12 month high of $17.47. The business has a 50 day simple moving average of $12.43 and a 200-day simple moving average of $9.38.

Analyst Ratings Changes

A number of research firms have recently issued reports on NPCE. JPMorgan Chase & Co. boosted their target price on NeuroPace from $9.00 to $14.00 and gave the company an “overweight” rating in a report on Tuesday, December 17th. UBS Group began coverage on shares of NeuroPace in a research note on Tuesday, January 21st. They issued a “buy” rating and a $17.00 price objective on the stock. Finally, Wells Fargo & Company raised their target price on shares of NeuroPace from $13.00 to $17.00 and gave the stock an “overweight” rating in a research note on Thursday, January 30th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $14.80.

Institutional Investors Weigh In On NeuroPace

Hedge funds and other institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets acquired a new position in shares of NeuroPace during the 4th quarter worth $29,000. Wells Fargo & Company MN boosted its holdings in NeuroPace by 54.2% during the fourth quarter. Wells Fargo & Company MN now owns 6,483 shares of the company’s stock worth $73,000 after buying an additional 2,279 shares in the last quarter. MetLife Investment Management LLC acquired a new position in NeuroPace during the fourth quarter worth about $103,000. Cubist Systematic Strategies LLC purchased a new position in NeuroPace in the fourth quarter valued at about $112,000. Finally, Birchview Capital LP acquired a new stake in shares of NeuroPace during the 4th quarter valued at approximately $112,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.